New medications that spur weight loss and treat diabetes have been using the public—as well as the pharmaceutical sector—by storm. The newest entrant, Zepbound, just lately joined Ozempic, Wegovy, Victoza and Other individuals in a expanding course of medications identified as GLP-1 receptor agonists.In 2005 a artificial Model known as exenatid